OWC Pharmaceutical Research Corp., an Israel-based developer of cannabinoid-based therapies targeting a variety of different indications, announced on Wednesday that it "is offering new and alternative hope to patients diagnosed with chronic pain."
The company's wholly owned subsidiary, One World Cannabis Ltd., has already filed two provisional patent applications with the USPTO related to the development of two unique formulations that include cannabis extracts and a new delivery system to treat fibromyalgia and migraines, and has begun researching and developing new cannabis-based therapies to help alleviate the suffering of patients experiencing enduring pain.
The news comes about after the FDA recently announced to increase existing heart attack and stroke warnings for both over-the-counter and prescription non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), which are typically used to treat chronic pain. The cannabis-based novel treatment employed by One World Cannabis could be an alternative to NSAIDs to treat long-lasting pain and fever from many different long- and short-term medical conditions.
In addition, the cannabis-based treatment will provide physicians, as well as patients, with the ability to control and administrate optimal dosage, thus offering an alternative to current delivery systems that are not acceptable to scientists and physicians, such as smoking marijuana, edibles and oil extracts with no substantial dosage control, according to OWC.